 |
|
Atorvastatin for the Treatment of Mild to Moderate Alzheimer Disease
Preliminary Results
D. Larry Sparks, PhD;
Marwan N. Sabbagh, MD;
Donald J. Connor, PhD, PhD;
Jean Lopez, MSN, CNRN;
Lenore J. Launer, PhD;
Patrick Browne, MD;
Dawn Wasser, BS;
Sherry Johnson-Traver;
Jeff Lochhead, BS;
Chuck Ziolwolski, MS
Arch Neurol. 2005;62:753-757.
Background Laboratory evidence of cholesterol-induced production of amyloid  as a putative neurotoxin precipitating Alzheimer disease, along with epidemiological evidence, suggests that cholesterol-lowering statin drugs may favorably influence the progression of the disorder.
Objective To determine if treatment with atorvastatin calcium affects the cognitive and/or behavioral decline in patients with mild to moderate Alzheimer disease.
Design Pilot intention-to-treat, proof-of-concept, double-blind, placebo-controlled, randomized (1:1) trial with a 1-year exposure to once-daily atorvastatin calcium (80 mg; two 40-mg tablets) or placebo using last observation carried forward analysis of covariance as the primary method of statistical assessment.
Participants Individuals with mild to moderate Alzheimer disease (Mini-Mental State Examination score of 12-28) were recruited. Of the 98 participants providing informed consent, 71 were eligible for randomization, 67 were randomized, and 63 subjects completed the 3-month visit and were considered evaluable.
Main Outcome Measures The primary outcome measures were change in Alzheimer's Disease Assessment Scale–cognitive subscale and the Clinical Global Impression of Change Scale scores. The secondary outcome measures included scores on the Mini-Mental State Examination, Geriatric Depression Scale, the Neuropsychiatric Inventory Scale, and the Alzheimer’s Disease Cooperative Study–Activities of Daily Living Inventory. The tertiary outcome measures included total cholesterol, low-density lipoprotein cholesterol, and very low-density lipoprotein cholesterol levels.
Results Atorvastatin reduced circulating cholesterol levels and produced a positive signal on each of the clinical outcome measures compared with placebo. This beneficial effect reached significance for the Geriatric Depression Scale and the Alzheimer's Disease Assessment Scale–cognitive subscale at 6 months and was significant at the level of a trend for the Alzheimer's Disease Assessment Scale–cognitive subscale, Clinical Global Impression of Change Scale, and Neuropsychiatric Inventory Scale at 12 months assessed by analysis of covariance with last observation carried forward.
Conclusion Atorvastatin treatment may be of some clinical benefit and could be established as an effective therapy for Alzheimer disease if the current findings are substantiated by a much larger multicenter trial.
Author Affiliations: Sun Health Research Institute, Sun City, Ariz (Drs Sparks, Sabbagh, and Connor, Mss Lopez and Johnson-Traver, and Messrs Lochhead and Ziolwolski); National Institute on Aging, Bethesda, Md (Dr Launer); and Departments of Cardiology (Dr Browne) and Pharmacy (Ms Wasser), Walter O. Boswell Hospital, Sun City.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
STATIN THERAPY IS ASSOCIATED WITH REDUCED NEUROPATHOLOGIC CHANGES OF ALZHEIMER DISEASE
Golomb et al.
Neurology 2008;70:2349-2330.
FULL TEXT
Lovastatin inhibits formation of AA amyloid
van der Hilst et al.
J. Leukoc. Biol. 2008;83:1295-1299.
ABSTRACT
| FULL TEXT
Independent Inhibition of Alzheimer Disease {beta}- and {gamma}-Secretase Cleavage by Lowered Cholesterol Levels
Grimm et al.
J. Biol. Chem. 2008;283:11302-11311.
ABSTRACT
| FULL TEXT
Statin-Induced Heme Oxygenase-1 Increases NF-{kappa}B Activation and Oxygen Radical Production in Cultured Neuronal Cells Exposed to Lipopolysaccharide
Hsieh et al.
Toxicol Sci 2008;102:150-159.
ABSTRACT
| FULL TEXT
Simvastatin-Induced Heme Oxygenase-1 Increases Apoptosis of Neuro 2A Cells in Response to Glucose Deprivation
Hsieh et al.
Toxicol Sci 2008;101:112-121.
ABSTRACT
| FULL TEXT
Association of statin use with cognitive decline in elderly African Americans
Szwast et al.
Neurology 2007;69:1873-1880.
ABSTRACT
| FULL TEXT
Statins Differentially Affect Amyloid Precursor Protein Metabolism in Presymptomatic PS1 and Non-PS1 Subjects
Hinerfeld et al.
Arch Neurol 2007;64:1672-1673.
FULL TEXT
Medication Use as a Confounding Factor in the Use of the Cerebrospinal Fluid tau/beta-Amyloid42 Ratio
Wong
Arch Neurol 2007;64:1357-1357.
FULL TEXT
Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease
Li et al.
Neurology 2007;69:878-885.
ABSTRACT
| FULL TEXT
Serum cholesterol changes after midlife and late-life cognition: Twenty-one-year follow-up study
Solomon et al.
Neurology 2007;68:751-756.
ABSTRACT
| FULL TEXT
The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deterioration
Ellul et al.
J. Neurol. Neurosurg. Psychiatry 2007;78:233-239.
ABSTRACT
| FULL TEXT
Green Banana*: Dementia Epidemiology Research: It Is Time to Modify the Focus of Research
Kuller
J. Gerontol. A Biol. Sci. Med. Sci. 2006;61:1314-1318.
ABSTRACT
| FULL TEXT
Discovery of Novel Hippocampal Neurogenic Agents by Using an in Vivo Stable Isotope Labeling Technique
Shankaran et al.
J. Pharmacol. Exp. Ther. 2006;319:1172-1181.
ABSTRACT
| FULL TEXT
Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.
Burns and O'Brien
J Psychopharmacol 2006;20:732-755.
ABSTRACT
Simvastatin-Induced Decline in Cognition
Padala et al.
The Annals of Pharmacotherapy 2006;40:1880-1883.
ABSTRACT
| FULL TEXT
Lipid lowering agents to delay cognitive decline in Alzheimer's disease?
de Leeuw
J. Neurol. Neurosurg. Psychiatry 2005;76:1611-1613.
FULL TEXT
The effect of cholesterol in Alzheimer's disease.
Lavigne
AM J ALZHEIMERS DIS OTHER DEMEN 2005;20:330-330.
Letter to the author
Reiss
AM J ALZHEIMERS DIS OTHER DEMEN 2005;20:330-330.
Mechanisms of Statin-mediated Inhibition of Small G-protein Function
Cordle et al.
J. Biol. Chem. 2005;280:34202-34209.
ABSTRACT
| FULL TEXT
|
